Antibiotics Market to Notice Prominent Growth of USD 49.8 billion by 2030, Size, Share, Trends, Demand and Industry Growth

1. EXECUTIVE SUMMARY
2. INTRODUCTION
   2.1. Overview of Antibiotics
   2.2. Characteristics of an Ideal Antibiotic
   2.3. Advantages of Antibiotics
   2.4. Classification of Antibiotics
   2.5. History of Antibiotics
   2.6. Innovations in Antibiotics
   2.7. Mechanism of Action of Antibiotics
   2.8. Challenges associated with the use of Antibiotics
   2.9. Future Perspectives
3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
   3.1. Approved Antibiotic Generics: Overall Market Landscape
   3.1.1. Analysis by Year of Approval
   3.1.2. Analysis by Region(s) of Approval
   3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
   3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
   3.1.5. Analysis by Mechanism of Action
   3.1.6. Analysis by Spectrum of Activity
   3.1.7. Analysis by Type of Target Bacteria(s)
   3.1.8. Analysis by Target Bacterial Strain(s)
   3.1.9. Analysis by Target Disease Indication(s)
   3.1.10. Analysis by Nature of Source
   3.1.11. Analysis by Type of Therapy
   3.1.12. Analysis by Route(s) of Administration
   3.1.13. Analysis by Dosage Form(s)
   3.1.14. Analysis by Type of Patient Population (based on Age)
   3.1.15. Analysis by Type of Patient Population (based on Gender)

3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
   4.1. Approved Antibiotic Brands: Overall Market Landscape
   4.1.1. Analysis by Year of Approval
   4.1.2. Analysis by Region(s) of Approval
   4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
   4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
   4.1.5. Analysis by Mechanism of Action
   4.1.6. Analysis by Spectrum of Activity
   4.1.7. Analysis by Type of Target Bacteria
   4.1.8. Analysis by Target Bacterial Strain(s)
   4.1.9. Analysis by Target Disease Indication(s)
   4.1.10. Analysis by Nature of Source
   4.1.11. Analysis by Type of Therapy
   4.1.12. Analysis by Route(s) of Administration
   4.1.13. Analysis by Dosage Form(s)
   4.1.14. Analysis by Type of Patient Population (based on Age)
   4.1.15. Analysis by Type of Patient Population (based on Gender)
   4.1.16. Analysis by Type of Innovation

4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
   5.1. Clinical -Stage Antibiotics: Overall Market Landscape
   5.1.1. Analysis by Status of Development
   5.1.2. Analysis by Stage of Development
   5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
   5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
   5.1.5. Analysis by Mechanism of Action
   5.1.6. Analysis by Spectrum of Activity
   5.1.7. Analysis by Type of Target Bacteria(s)
   5.1.8. Analysis by Target Bacterial Strain(s)
   5.1.9. Analysis by Target Disease Indication(s)
   5.1.10. Analysis by Therapeutic Area(s)
   5.1.11. Analysis by Nature of Source
   5.1.12. Analysis by Type of Therapy
   5.1.13. Analysis by Route(s) of Administration
   5.1.14. Analysis by Dosage Form(s)
   5.1.15. Analysis by Dosage Strength
   5.1.16. Analysis by Dosage Frequency
   5.1.17. Analysis by Dosing Period
   5.1.18. Analysis by Type of Patient Population (based on Age)
   5.1.19. Analysis by Type of Patient Population (based on Gender)
   5.1.20. Analysis by Special Designation Received

5.2. Clinical -Stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

6. COMPANY PROFILES
   6.1. Bristol-Myers Squibb
   6.1.1. Company Overview
   6.1.2. Key Executives
   6.1.3. Financial Information
   6.1.4. Product Portfolio
   6.1.5. Recent Developments
   6.1.6. Key Strategies
   6.1.7. Key Focus Areas
   6.1.8. Expert Opinion

6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion

6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion

6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion

6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion

6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion

6.7. Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
   7.1. Partnership Models
   7.2. Antibiotics: List of Partnerships and Collaborations
   7.2.1. Analysis by Year of Partnership
   7.2.2. Analysis by Type of Partnership
   7.2.3. Analysis by Type of Partner
   7.2.4. Analysis by Company Size
   7.2.5. Local and International Agreements
   7.2.6. Intracontinental and Intercontinental Agreements
   7.2.7. Most Active Players: Analysis by Number of Partnerships
   7.2.8. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
   8.1. Analysis Methodology and Key Parameters
   8.2. Antibiotics: Clinical Trial Analysis
   8.2.1. Analysis by Trial Registration Year
   8.2.2. Analysis by Trial Status
   8.2.3. Analysis by Trial Phase
   8.2.4. Analysis by Type of Patient Population (based on Gender)
   8.2.5 Word Cloud Analysis: Key Focus Areas
   8.2.6. Analysis by Type of Sponsor
   8.2.7. Analysis by Geography
   8.2.8. Most Active Industry Players: Analysis by Number of Trials
   8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials
9. KEY OPINION LEADERS
   9.1. Assumptions and Key Parameters
   9.2. Methodology
   9.3. Antibiotics: Key Opinion Leaders (KOLs)
   9.3.1. Analysis by Type of KOL
   9.3.2. Analysis by Qualification
   9.3.3. Analysis by Type of Organization
   9.3.4. Analysis by Affiliated Organization
   9.3.5. Analysis by Geographical Location of KOLs
   9.3.6. Analysis by Target Disease Indication(s)
   9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
   9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
   9.3.9. Most Prominent KOLs: Analysis by RA score
   9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
   9.3.11. Concluding Remarks
10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
    10.1. Antibiotics Industry: Drug-Pricing Analysis
    10.2. Antibiotics Industry: Outsourcing Trends
    10.3. Antibiotics Industry: Impact of COVID-19
11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
    11.1. Chapter Overview
    11.2. Methodology
    11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
    11.3.1. Dovprela (TB Alliance)
    11.3.1.1. Drug Overview
    11.3.1.2. Success Protocol Analysis

11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis

11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis

11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis

11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis

11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis

11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
    12.1. Chapter Overview
    12.2. Key Assumptions and Methodology
    12.3. Global Antibiotics Market, 2023-2030
    12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2030
    12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2030
    12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2030
    12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2030
    12.3.1.4. Antibiotics Market for Macrolides, 2023-2030
    12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2030
    12.3.1.6. Antibiotics Market for Penicillins, 2023-2030
    12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2030
    12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2030
    12.3.1.9. Antibiotics Market for Other Classes, 2023-2030

12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2030
12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2030
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2030
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2030
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2030
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2030
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2030
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2030
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2030
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2030
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2030

12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2030
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2030

12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2030
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2030
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2030

12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2030
12.3.5.1. Antibiotics Market in North America, 2023-2030
12.3.5.2. Antibiotics Market in Europe, 2023-2030
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2030
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2030

12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo®: Sales Forecast, 2023-2030
12.3.6.2. Arikayce®: Sales Forecast, 2023-2030
12.3.6.3. Baxdela™: Sales Forecast, 2023-2030
12.3.6.4. Dalacin C: Sales Forecast, 2023-2030
12.3.6.5. Dovprela®: Sales Forecast, 2023-2030
12.3.6.6. Emrok: Sales Forecast, 2023-2030
12.3.6.7. Emrok-O: Sales Forecast, 2023-2030
12.3.6.8. Fetroja®: Sales Forecast, 2023-2030
12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2030
12.3.6.10. Lasvic®: Sales Forecast, 2023-2030
12.3.6.11. Nuzyra®: Sales Forecast, 2023-2030
12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2030
12.3.6.13. Ozanex™: Sales Forecast, 2023-2030
12.3.6.14. Quofenix: Sales Forecast, 2023-2030
12.3.6.15. Recarbrio™: Sales Forecast, 2023-2030
12.3.6.16. Seysara™: Sales Forecast, 2023-2030
12.3.6.17. Solosec®: Sales Forecast, 2023-2030
12.3.6.18. Vabomere™: Sales Forecast, 2023-2030
12.3.6.19. Xenleta™: Sales Forecast, 2023-2030
12.3.6.20. XEPI™: Sales Forecast, 2023-2030
12.3.6.21. Xerava™: Sales Forecast, 2023-2030
12.3.6.22. Xydalba®: Sales Forecast, 2023-2030
12.3.6.23. Youxitai: Sales Forecast, 2023-2030
12.3.6.24. Zemdri™: Sales Forecast, 2023-2030
12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2030
12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2030

12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2030
12.3.7.2. CONTEPO™: Sales Forecast, 2023-2030
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2030
12.3.7.4. MBK-01: Sales Forecast, 2023-2030
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2030
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2030
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2030
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2030
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2030
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2030
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2030
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2030
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2030
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2030
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2030
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2030

13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Executive Summary: Overall Market Landscape of Approved Antibiotic Generics
Figure 1.2 Executive Summary: Overall Market Landscape of Approved Antibiotic Brands
Figure 1.3 Executive Summary: Overall Market Landscape of Clinical -Stage Antibiotics
Figure 1.4 Executive Summary: Partnerships and Collaborations
Figure 1.5 Executive Summary: Clinical Trial Analysis
Figure 1.6 Executive Summary: Key Opinion Leaders
Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 2.1 Classification of Antibiotics
Figure 2.2 History of Antibiotics
Figure 2.3 Mechanism of Action of Antibiotics
Figure 3.1 Approved Antibiotic Generics: Distribution by Year of Approval
Figure 3.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Figure 3.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Figure 3.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 3.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 3.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Figure 3.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Figure 3.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Figure 3.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Figure 3.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Figure 3.11 Approved Antibiotic Generics: Distribution by Nature of Source
Figure 3.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Figure 3.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Figure 3.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Figure 3.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Figure 3.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Figure 3.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Figure 3.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Figure 3.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Figure 3.20 Most Active Players: Distribution by Number of Approved Generics
Figure 4.1 Approved Antibiotic Brands: Distribution by Year of Approval
Figure 4.2 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Figure 4.3 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Figure 4.4 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 4.5 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Figure 4.6 Approved Antibiotic Brands: Distribution by Mechanism of Action
Figure 4.7 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Figure 4.8 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Figure 4.9 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Figure 4.10 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Figure 4.11 Approved Antibiotic Brands: Distribution by Nature of Source
Figure 4.12 Approved Antibiotic Brands: Distribution by Type of Therapy
Figure 4.13 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Figure 4.14 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Figure 4.15 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Figure 4.16 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Figure 4.17 Approved Antibiotic Brands: Distribution by Type of Innovation
Figure 4.18 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Figure 4.19 Approved Antibiotic Brand Developers: Distribution by Company Size
Figure 4.20 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Figure 4.21 Most Active Players: Distribution by Number of Approved Brands
Figure 5.1 Clinical -Stage Antibiotics: Distribution by Status of Development
Figure 5.2 Clinical -Stage Antibiotics: Distribution by Stage of Development
Figure 5.3 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 5.4 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 5.5 Clinical -Stage Antibiotics: Distribution by Mechanism of Action
Figure 5.6 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity
Figure 5.7 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Figure 5.8 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Figure 5.9 Clinical-Stage Antibiotics: Distribution by Target Disease Indication(s)
Figure 5.10 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)
Figure 5.11 Clinical -Stage Antibiotics: Distribution by Nature of Source
Figure 5.12 Clinical -Stage Antibiotics: Distribution by Type of Therapy
Figure 5.13 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration
Figure 5.14 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)
Figure 5.15 Clinical -Stage Antibiotics: Distribution by Dosage Strength
Figure 5.16 Clinical -Stage Antibiotics: Distribution by Dosage Frequency
Figure 5.17 Clinical -Stage Antibiotics: Distribution by Dosing Period
Figure 5.18 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Figure 5.19 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Figure 5.20 Clinical -Stage Antibiotics: Distribution by Special Designation Received
Figure 5.21 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment
Figure 5.22 Clinical -Stage Antibiotic Developers: Distribution by Company Size
Figure 5.23 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters
Figure 5.24 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Figure 5.25 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Figure 6.1 Bristol-Myers Squibb: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.2 Bristol-Myers Squibb: Key Strategies
Figure 6.3 Bristol-Myers Squibb: Key Focus Areas
Figure 6.4 Daiichi Sankyo: Annual Revenues, 2017-9M 2022 (JPY Billion)
Figure 6.5 Daiichi Sankyo: Key Strategies
Figure 6.6 Daiichi Sankyo: Key Focus Areas
Figure 6.7 GlaxoSmithKline: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.8 GlaxoSmithKline: Key Strategies
Figure 6.9 GlaxoSmithKline: Key Focus Areas
Figure 6.10 Melinta Therapeutics: Annual Revenues, 2017-6M 2019 (USD Billion)
Figure 6.11 Melinta Therapeutics: Key Strategies
Figure 6.12 Melinta Therapeutics: Key Focus Areas
Figure 6.13 Merck: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.14 Merck: Key Strategies
Figure 6.15 Merck: Key Focus Areas
Figure 6.16 Pfizer: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 6.17 Pfizer: Key Strategies
Figure 6.18 Pfizer: Key Focus Areas
Figure 6.19 Company Profiles: Concluding Remarks
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Company Size
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 7.8 Partnerships and Collaborations: Local and International Agreements
Figure 7.9 Partnerships and Collaborations: Distribution by Geography
Figure 7.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 7.11 Most Active Players: Distribution by Number of Partnerships
Figure 7.12 Partnerships and Collaborations: Concluding Remarks
Figure 8.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Figure 8.5 Clinical Trial Analysis: Key Focus Areas
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 8.7 Clinical Trial Analysis: Distribution by Geography
Figure 8.8 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 8.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 8.10 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Figure 8.11 Most Active Industry Players: Analysis by Number of Trials
Figure 8.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 9.1 KOL Analysis: Distribution by Type of KOL
Figure 9.2 KOL Analysis: Distribution by Qualification
Figure 9.3 KOL Analysis: Distribution by Type of Organization
Figure 9.4 KOL Analysis: Distribution by Affiliated Organization
Figure 9.5 KOL Analysis: Distribution by Geographical Location of KOLs
Figure 9.6 KOL Analysis: Distribution by Target Disease Indication(s)
Figure 9.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 9.8 Most Prominent KOLs: Peer Group 1 (Other Types of Investigators)
Figure 9.9 Most Prominent KOLs: Distribution by RA score
Figure 9.10 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Figure 9.11 KOL Analysis: Concluding Remarks
Figure 10.1. Drug-Pricing Analysis: Distribution by Geography
Figure 10.2. Key Antibiotic Developers: Outsourcing Trends
Figure 11.1. Dovprela (TB Alliance): Success Protocol Analysis
Figure 11.2. Fetroja (Shionogi): Success Protocol Analysis
Figure 11.3 Kimyrsa (Melinta Therapeutics): Success Protocol Analysis
Figure 11.4 Recarbrio (Merck): Success Protocol Analysis
Figure 11.5 Quofenix (Menarini): Success Protocol Analysis
Figure 11.6 Xenleta (Nabriva Therapeutics): Success Protocol Analysis
Figure 11.7 Success Protocol Analysis: Concluding Remarks
Figure 12.1 Global Antibiotics Market, 2023-2030 (USD Billion)
Figure 12.2 Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2030 (USD Billion)
Figure 12.3 Antibiotics Market for Aminoglycosides, 2023-2030 (USD Billion)
Figure 12.4 Antibiotics Market for Cephalosporins, 2023-2030 (USD Billion)
Figure 12.5 Antibiotics Market for Fluoroquinolones, 2023-2030 (USD Billion)
Figure 12.6 Antibiotics Market for Macrolides, 2023-2030 (USD Billion)
Figure 12.7 Antibiotics Market for Oxazolidinones, 2023-2030 (USD Billion)
Figure 12.8 Antibiotics Market for Penicillins, 2023-2030 (USD Billion)
Figure 12.9 Antibiotics Market for Sulphonamides, 2023-2030 (USD Billion)
Figure 12.10 Antibiotics Market for Tetracyclines, 2023-2030 (USD Billion)
Figure 12.11 Antibiotics Market for Other Classes, 2023-2030 (USD Billion)
Figure 12.12 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030 (USD Billion)
Figure 12.13 Antibiotics Market for Bacterial Infections, 2023-2030 (USD Billion)
Figure 12.14 Antibiotics Market for Dermatological/ Skin Infections, 2023-2030 (USD Billion)
Figure 12.15 Antibiotics Market for Gastrointestinal Infections, 2023-2030 (USD Billion)
Figure 12.16 Antibiotics Market for Nephrological Infections, 2023-2030 (USD Billion)
Figure 12.17 Antibiotics Market for Pulmonary Infections, 2023-2030 (USD Billion)
Figure 12.18 Antibiotics Market for Reproductive Tract Infections, 2023-2030 (USD Billion)
Figure 12.19 Antibiotics Market for Respiratory Tract Infections, 2023-2030 (USD Billion)
Figure 12.20 Antibiotics Market for Sexually Transmitted Diseases, 2023-2030 (USD Billion)
Figure 12.21 Antibiotics Market for Urinary Tract Infections, 2023-2030 (USD Billion)
Figure 12.22 Antibiotics Market for Other Bacterial Infections, 2023-2030 (USD Billion)
Figure 12.23 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030 (USD Billion)
Figure 12.24 Antibiotics Market for Monotherapies, 2023-2030 (USD Billion)
Figure 12.25 Antibiotics Market for Combination Therapies, 2023-2030 (USD Billion)
Figure 12.26 Antibiotics Market: Distribution by Route of Administration, 2023 and 2030 (USD Billion)
Figure 12.27 Antibiotics Market for Intravenous Therapies, 2023-2030 (USD Billion)
Figure 12.28 Antibiotics Market for Oral Therapies, 2023-2030 (USD Billion)
Figure 12.29 Antibiotics Market: Distribution by Geography, 2023 and 2030 (USD Billion)
Figure 12.30 Antibiotics Market in North America, 2023-2030 (USD Billion)
Figure 12.31 Antibiotics Market in Europe, 2023-2030 (USD Billion)
Figure 12.32 Antibiotics Market in Asia-Pacific, 2023-2030 (USD Billion)
Figure.13.33 Antibiotics Market in Rest of the World, 2023-2030 (USD Billion)
Figure.13.34 Aemcolo®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.35 Arikayce®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.36 Baxdela™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.37 Dalacin C: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.38 Dovprela®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.39 Emrok: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.40 Emrok-O: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.41 Fetroja®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.42 Kimyrsa™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.43 Lasvic®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.44 Nuzyra®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.45 Orbactiv™/Tenkasi: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.46 Ozanex™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.47 Quofenix: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.48 Recarbrio™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.49 Seysara™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.50 Solosec®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.51 Vabomere™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.52 Xenleta™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.53 XEPI™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.54 Xerava™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.55 Xydalba®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.56 Youxitai: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.57 Zemdri™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.58 Zerbaxa®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.59 Zyvoxam®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.60 Cefepime-Taniborbactam: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.61 CONTEPO™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.62 Gepotidacin (GSK2140944): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.63 MBK-01: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.64 MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.65 Nafithromycin (WCK 4873): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.66 RHB-104 (rifabutin, rifabutin, and clofazimin): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.67. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.68 Ridinilazole (SMT 19969): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.69 Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.70 Tebipenem HBr: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.71 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.72 WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.73 XNW4107 (Funobactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.74 Zabofloxacin: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.75 Zoliflodacin (ETX0914): Sales Forecast, 2023-2030 (USD Billion)

List Of Tables

Table 3.1 Approved Antibiotic Generics: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action, and Spectrum of Activity
Table 3.2 Approved Antibiotic Generics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 3.3 Approved Antibiotic Generics: Information on Route(s) of Administration. Dosage Form(s), and Type of Patient Population (based on Age and Gender)
Table 3.4 Approved Antibiotic Generics: List of Developers
Table 4.1 Approved Antibiotic Brands: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 4.2 Approved Antibiotic Brands: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 4.3 Approved Antibiotic Brands: Information on Route(s) of Administration, Dosage Form(s), Type of Patient Population (based on Age and Gender) and Type of Innovation
Table 4.4 Approved Antibiotic Brands: List of Developers
Table 5.1 Clinical -Stage Antibiotics: Information on Status of Development, Stage of Development, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 5.2 Clinical -Stage Antibiotics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Therapeutic Area, Nature of Source and Type of Therapy
Table 5.3 Clinical -Stage Antibiotics: Information on Route(s) of Administration,Dosage Form(s), Dosage Strength, Dosage Frequency and Dosing Period
Table 5.4 Clinical -Stage Antibiotics: Information on Type of Patient Population (based on Age and Gender)
Table 5.5 Clinical -Stage Antibiotics: List of Developers
Table 6.1 Bristol-Myers Squibb: Product Portfolio
Table 6.2 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.3 Daiichi Sankyo: Product Portfolio
Table 6.4 Daiichi Sankyo: Recent Developments and Future Outlook
Table 6.5 GlaxoSmithKline: Product Portfolio
Table 6.6 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.7 Melinta Therapeutics: Product Portfolio
Table 6.8 Melinta Therapeutics: Recent Developments and Future Outlook
Table 6.9 Merck: Product Portfolio
Table 6.10 Merck: Recent Developments and Future Outlook
Table 6.11 Pfizer: Product Portfolio
Table 6.12 Pfizer: Recent Developments and Future Outlook
Table 7.1 Antibiotics: List of Partnerships and Collaborations
Table 8.1. Antibiotics: List of Clinical Trials
Table 9.1. Antibiotics: List of Key Opinion Leaders (KOLs)
Table 10.1. Antibiotics Industry: List of Recent Expansions
Table 11.1 Sales Forecast: List of Approved Antibiotics
Table 12.1 Sales Forecast: List of Clinical-stage Antibiotics
Table 13.1 Approved Antibiotic Generics: Distribution by Year of Approval
Table 13.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Table 13.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Table 13.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Table 13.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Table 13.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Table 13.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Table 13.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Table 13.11 Approved Antibiotic Generics: Distribution by Nature of Source
Table 13.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Table 13.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Table 13.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Table 13.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Table 13.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Table 13.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Table 13.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Table 13.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Table 13.20 Most Active Players: Distribution by Number of Approved Generics
Table 13.21 Approved Antibiotic Brands: Distribution by Year of Approval
Table 13.22 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Table 13.23 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Table 13.24 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.25 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.26 Approved Antibiotic Brands: Distribution by Mechanism of Action
Table 13.27 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Table 13.28 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Table 13.29 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Table 13.30 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Table 13.31 Approved Antibiotic Brands: Distribution by Nature of Source
Table 13.32 Approved Antibiotic Brands: Distribution by Type of Therapy
Table 13.33 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Table 13.34 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Table 13.35 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Table 13.36 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Table 13.37 Approved Antibiotic Brands: Distribution by Type of Innovation
Table 13.38 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Table 13.39 Approved Antibiotic Brand Developers: Distribution by Company Size
Table 13.40 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Table 13.41 Most Active Players: Distribution by Number of Approved Brands
Table 13.42 Clinical -Stage Antibiotics: Distribution by Status of Development
Table 13.43 Clinical -Stage Antibiotics: Distribution by Stage of Development
Table 13.44 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.45 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.46 Clinical -Stage Antibiotics: Distribution by Mechanism of Action
Table 13.47 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity
Table 13.48 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Table 13.49 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Table 13.50 Clinical -Stage Antibiotics: Distribution by Target Disease Indication(s)
Table 13.51 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)
Table 13.52 Clinical -Stage Antibiotics: Distribution by Nature of Source
Table 13.53 Clinical -Stage Antibiotics: Distribution by Type of Therapy
Table 13.54 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration
Table 13.55 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)
Table 13.56 Clinical -Stage Antibiotics: Distribution by Dosage Strength
Table 13.57 Clinical -Stage Antibiotics: Distribution by Dosage Frequency
Table 13.58 Clinical -Stage Antibiotics: Distribution by Dosing Period
Table 13.59 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Table 13.60 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Table 13.61 Clinical -Stage Antibiotics: Distribution by Special Designation Received
Table 13.62 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment
Table 13.63 Clinical -Stage Antibiotic Developers: Distribution by Company Size
Table 13.64 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters
Table 13.65 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Table 13.66 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Table 13.67 Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.68 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.69 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.70 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.72 Partnerships and Collaborations: Distribution by Company Size
Table 13.73 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.74 Partnerships and Collaborations: Local and International Agreements
Table 13.75 Partnerships and Collaborations: Distribution by Geography
Table 13.76 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 13.77 Most Active Players: Distribution by Number of Partnerships
Table 13.78 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.79 Clinical Trial Analysis: Distribution by Trial Status
Table 13.80 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.81 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Table 13.82 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.83 Clinical Trial Analysis: Distribution by Geography
Table 13.84 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 13.85 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 13.86 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Table 13.87 Most Active Industry Players: Analysis by Number of Trials
Table 13.88 Most Active Non-Industry Players: Analysis by Number of Trials
Table 13.89 KOL Analysis: Distribution by Type of KOL
Table 13.90 KOL Analysis: Distribution by Qualification
Table 13.91 KOL Analysis: Distribution by Type of Organization
Table 13.92 KOL Analysis: Distribution by Affiliated Organization
Table 13.93 KOL Analysis: Distribution by Geographical Location of KOLs
Table 13.94 KOL Analysis: Distribution by Target Disease Indication(s)
Table 13.95 Global Antibiotics Market: Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.96 Antibiotics Market: Distribution by Type of Antibiotic (based on Drug Class), 2023 and 2030 (USD Billion)
Table 13.97 Antibiotics Market for Aminoglycosides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.98 Antibiotics Market for Cephalosporins, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.99 Antibiotics Market for Fluoroquinolones, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.100 Antibiotics Market for Macrolides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.101 Antibiotics Market for Oxazolidinones, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.102 Antibiotics Market for Penicillins, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.103 Antibiotics Market for Sulphonamides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.104 Antibiotics Market for Tetracyclines, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.105 Antibiotics Market for Other Classes, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.106 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030 (USD Billion)
Table 13.107 Antibiotics Market for Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.108 Antibiotics Market for Dermatological/ Skin Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.109 Antibiotics Market for Gastrointestinal Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.110 Antibiotics Market for Nephrological Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.111 Antibiotics Market for Pulmonary Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.112 Antibiotics Market for Reproductive Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.113 Antibiotics Market for Respiratory Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.114 Antibiotics Market for Sexually Transmitted Diseases, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.115 Antibiotics Market for Urinary Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.116 Antibiotics Market for Other Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.117 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030 (USD Billion)
Table 13.118 Antibiotics Market for Monotherapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.119 Antibiotics Market for Combination Therapies, 2023-2030 (USD Billion)
Table 13.120 Antibiotics Market: Distribution by Route of Administration, 2023 and 2030 (USD Billion)
Table 13.121 Antibiotics Market for Intravenous Therapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.122 Antibiotics Market for Oral Therapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.123 Antibiotics Market: Distribution by Geography, 2023 and 2030
Table 13.124 Antibiotics Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.125 Antibiotics Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.126 Antibiotics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.127 Antibiotics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.128 Aemcolo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.129 Arikayce®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.130 Baxdela™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion))
Table 13.131 Dalacin C: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.132 Dovprela®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.133 Emrok: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.134 Emrok-O: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.135 Fetroja®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.136 Kimyrsa™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.137 Lasvic®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.138 Nuzyra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.139 Orbactiv™/Tenkasi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.140 Ozanex™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.141 Quofenix: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.142 Recarbrio™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.143 Seysara™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.144 Solosec®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.145 Vabomere™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.146 Xenleta™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.147 XEPI™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.148 Xerava™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.149 Xydalba®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.150 Youxitai: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.151 Zemdri™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.152 Zerbaxa®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.153 Zyvoxam®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.154 Cefepime-Taniborbactam: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.155 CONTEPO™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.156 Gepotidacin (GSK2140944): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.157 MBK-01: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.158 MRX-4 (Contezolid Acefosamil): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.159 Nafithromycin (WCK 4873): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.160 RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.161 RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.162 Ridinilazole (SMT 19969): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.163 Sulopenem- etzadroxil- probenecid: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.164 Tebipenem HBr: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.165 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, , Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.166 WCK 5222 (cefepime + zidebactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.167 XNW4107 (Funobactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.168 Zabofloxacin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.169 Zoliflodacin (ETX0914): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. Abbott
2. ABAC Therapeutics
3. AbbVie
4. Aceragen
5. Acurx Pharmaceuticals
6. Affinivax (a subsidiary of GlaxoSmithKline) 
7. AGILeBiotics 
8. Alcon
9. Alfa Wassermann
10. Allecra Therapeutics
11. Angelini Pharma
12. Antimicrobials Working Group (AWG)
13. Aptuit
14. Ares Genetics (acquired by OpGen)
15. Arrevus (a subsidiary of Aceragen)
16. Astellas Pharma (formerly known as Fujisawa Pharmaceutical)
17. B. Braun
18. Basilea Pharmaceutica
19. Bayer
20. Bill & Melinda Gates Foundation
21. Bill & Melinda Gates Medical Research Institute
22. BIOASTER
23. Biocidium Biopharmaceuticals
24. bioMérieux
25. BioVersys 
26. Blacksmith Medicines
27. Boulos and Cooper Pharmaceuticals
28. Brii Biosciences
29. Bristol-Myers Squibb
30. Bugworks Research
31. Calibr
32. Cardiome Pharma
33. Catalent
34. Chia Tai Tianqing Pharmaceutical
35. Cipla
36. Colgate-Palmolive
37. Commonwealth Scientific and Industrial Research Organization
38. ContraFect
39. Cosmo Pharmaceuticals
40. Cosmo Technologies
41. Crestone
42. CrystalGenomics
43. Cubist Pharmaceuticals
44. Curetis
45. Daiichi Sankyo
46. Damascus Hospital
47. Debiopharm
48. Defense Threat Reduction Agency (DTRA)
49. DEINOVE
50. Department of Health and Human Services
51. Discuva (a subsidiary of Summit Therapeutics) 
52. Dongwha Pharmaceutical
53. Entasis Therapeutics
54. Er-Kim Pharmaceuticals
55. Eurofarma
56. Everest Medicines
57. EVERSANA
58. Evotec
59. Exeltis
60. Fedora Pharmaceuticals
61. Ferrer Internacional
62. Forest Laboratories
63. Forge Therapeutics (a subsidiary of Blacksmith Medicines)
64. Fosun Pharma
65. Foundation for Neglected Disease Research (FNDR)
66. French National Agency for the Safety of Medicines and Health Products (ANSM)
67. Fresenius Kabi
68. Fujifilm
69. Genentech
70. Gilead Sciences
71. GlaxoSmithKline
72. Global Antibiotic Research and Development Partnership (GARDP)
73. HanaVax
74. Hartford Healthcare
75. Helperby Therapeutics
76. Helsinki University Hospital
77. Hikma Pharmaceuticals
78. Hoffmann-La Roche
79. Hsiri Therapeutics
80. Huazhong University of Science and Technology
81. HUTCHMED
82. Idera Pharmaceuticals
83. Infex Therapeutics
84. Innoviva
85. Insmed
86. Institut Pasteur de Lille
87. InveniAI
88. Iterum Therapeutics
89. Janssen Pharmaceutical
90. JEIL Pharmaceutical
91. Juvabis
92. KBP Biosciences
93. Kyorin Pharmaceutical
94. Kyoto Pharmaceutical
95. Kyowa Hakko Bio
96. La Jolla Pharmaceutical Company
97. LANCET Pharmaceuticals
98. LegoChem Biosciences
99. LifeArc

100. Liverpool School of Tropical Medicine
101. Lupin
102. MacKay Memorial Hospital
103. Macleods Pharmaceuticals
104. Madam Therapeutics
105. Mahidol University
106. Maruho 
107. Medical College of Wisconsin
108. Medicines for Malaria Venture (MMV)
109. Medimetriks Pharmaceuticals
110. Medpace
111. Meiji Seika Pharma
112. Melinta Therapeutics
113. Merck
114. MGB Biopharma
115. MicuRx Pharmaceuticals
116. Mikrobiomik
117. Mitsubishi Tanabe Pharma